Learn more about Laxxon Medical's groundbreaking 3D printed oral GLP-1 asset, offering an alternative to injections in obesity treatments.

Counterfeit medicine is a threat to public health. Technologies like 3D printing and QR codes help protect both patients and drug integrity.

Laxxon Medical announced its participation in the 2024 BIO International Convention, to showcase its LXM.2 asset to potential partners.

LXM.2 is Laxxon Medical’s oral GLP-1 Agonist treatment for weight loss, offering patients a non-invasive, once-a-day treatment made...

Learn all about GLP-1 medications for diabetes and obesity, including benefits, side effects, and how they work.

Explore the future of drug delivery, Laxxon Medical's innovative 3D technology, and how controlled-release drugs are reshaping healthcare.

Join Dr.Catherine Gatza, our VP of Regulatory Affairs, at the World Orphan Drug Congress USA 2024, in Boston, Massachusetts.

Laxxon's extended-release Levodopa is revolutionizing Parkinson's treatment, increasing patient quality of life with improved medication.

3D screen printing could revolutionize the fight against counterfeit medication, innovating anti-counterfeiting measures for patient safety.

Learn how Laxxon Medical's 3D screen printing and QR codes combat counterfeit medicine. Discover the impact on safety and global healthcare.